Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor

Bahar Ataeinia; Christina Loberg; Hanna Kravets; Mohsen Beheshti; Dirk von Mallek; Felix M Mottaghy; Alexander Heinzel

doi:10.17179/excli2019-1220

Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor

EXCLI J. 2019 May 21:18:273-276. doi: 10.17179/excli2019-1220. eCollection 2019.

Authors

Bahar Ataeinia^{1

2}, Christina Loberg¹, Hanna Kravets¹, Mohsen Beheshti¹, Dirk von Mallek¹, Felix M Mottaghy^{1

3}, Alexander Heinzel¹

Affiliations

¹ Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
² Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.

Abstract

We present the case of a 77 year old male patient with metastatic pancreatic neuroendocrine tumor (NET). The patient was initially treated by extensive surgical resection that however, led to severe complications with delayed recovery. During follow-up, a number of new liver metastases were detected, one of which was in segment I with impending compression of the inferior vena cava. Due to age and general condition of the patient, instead of further surgical treatment, the patient received four cycles of ¹⁷⁷Lu-DOTATOC resulting in an overall partial response with successful tumor reduction in liver segment I, resolving an impending compression of vena cava.

Keywords: 177Lu-DOTATOC; PRRT; metastasis; neuroendocrine tumors.

Publication types

Case Reports